INTRODUCTION
P osttraumatic stress disorder (PTSD) is a condition that develops after exposure to a traumatic event. 1 Symptoms include intrusive re-experiencing of the traumatic event, avoidance of trauma-related stimuli, negative alterations in cognition and mood, and changes in arousal and reactivity.
1 PTSD effects 8.3% of Americans and is marked by significant symptom-related distress and functional impairment. 3 In addition to the decreased quality of life, 3 individuals with PTSD have a higher prevalence of cardiovascular, 4 metabolic, 5 and autoimmune disorders 6 when compared with those without PTSD. These factors taken in aggregate arguably make PTSD an important contributor to mortality and therefore, a priority for preventive health care.
Although literature strongly supports the assertion that patients with PTSD have increased overall mortality, the exact causes of that excess mortality have been more elusive. Understanding these causes may help elucidate potential targets for prevention. Most studies evaluating mortality in PTSD have been conducted in U.S. military Veterans. Though Veterans with PTSD have been documented to have twice the risk of death as those without PTSD, the causes remain unknown. 7 Published reports frequently demonstrate causes of death attributed to cardiovascular complications 7−12 and malignancy, 7, 12 but studies comparing Vietnam Veterans with PTSD with the general population have not found increased cardiovascular or malignancy-related deaths. 13, 14 Other studies have reported a high prevalence of external-cause mortality 7,13−15 among patients with PTSD. However, with the exception of suicide mortality, 7 ,13−18 a detailed analysis of specific external causes of death in this population has not been published yet.
Most published reports about external causes of death focus on Vietnam Veterans with PTSD. 7, 12, 14, 17, 19, 20 However, the limited research on external causes of death in other cohorts of Veterans has been less clear. 17, 20 Veterans with PTSD who served in Operation Enduring Freedom, Operation Iraqi Freedom, or Operation New Dawn have not been widely studied. These contemporary cohorts have higher percentages of young Veterans and women, 21 both of which may influence causes of death. 22 With advances in medicine and technology, Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn Veterans are more likely to survive combat injuries than previous generations, thereby increasing the prevalence of PTSD, 17, 21 pain disorder, 23 and pain-related opioid use 23 among survivors. Evaluating mortality across a diverse sample of Veterans may provide more inclusive data on causes of death related to PTSD.
In addition, causes of death among patients engaged in clinical treatment for PTSD are not well described. Although published reports demonstrate an elevated allcause mortality risk among treatment-seeking U.S. Veterans with PTSD, 13, 24 the treatment settings are rarefied (e.g., residential 13 and inpatient 18 ) and generalizability to a larger PTSD treatment population may be limited. Furthermore, between 2004 and 2013, the Veterans Health Administration underwent a clinical paradigm shift in the management of PTSD 25 by incorporating more individualized evidence-based psychotherapy into treatment plans. 26 Given the wide array of clinical manifestations and comorbidities associated with PTSD, access to tailored treatment modalities may have improved health outcomes among treatment-seeking Veterans by addressing individual needs. 18 Finally, the relationship between age and cause of death among patients with PTSD is not well known. Early research suggests that patients with PTSD may have accelerated cellular aging as evidenced by shorter telomere lengths 27 and may therefore be at increased risk for death. This may be related to chronic stress states compounded over many years. 13 In a 6-year longitudinal study of Vietnam Veterans with PTSD, hyperarousal symptoms were found to significantly increase over time. 18 It is plausible that this hyperarousal could increase rates of cardiovascular disease and death among older patients with chronic PTSD. Evaluating causes of death relative to age in patients with PTSD may be important for developing targeted interventions.
No study has comprehensively investigated specific causes of death by age group among contemporary treatment-seeking Veterans with PTSD and compared mortality rates with an age-and sex-matched U.S. general population. Stratifying causes of death by age may help determine if mortality related to chronic stress states appears later in life. The purpose of this study was to better understand the relationship between PTSD and mortality among a national sample of treatment-seeking Veterans with PTSD. The primary objectives were as follows: (1) to document the relative mortality for Veterans engaging in PTSD treatment compared with the U.S. population and (2) to determine the specific causes of death contributing to this mortality, thereby informing preventive interventions for patients and providers. 
METHODS

Department of Veterans
Study Population
Patients were drawn from an existing retrospective cohort of Veterans entering PTSD treatment at a VA facility (VA users) between October 1, 2008 and September 30, 2013. 28, 29 To avoid misclassification of PTSD status in VA administrative data, VA users included those who received a primary diagnosis of PTSD at two or more outpatient visits, at least one of which occurred in a mental health setting, over the course of 90 days. Requiring at least two PTSD diagnoses 30, 31 and using PTSD diagnoses made in mental health settings are both strategies to increase the positive predictive value of diagnostic data. 30 However, as access to individualized evidence-based psychotherapy for PTSD has only increased in clinical practice since 2008, 32 this data set was restricted to Veterans with new episodes of VA PTSD treatment in FY 2008 or later. When Veterans met inclusion criteria multiple times over the 6-year period, only the first episode was included. Qualifying Veterans were followed up for 1 year after index PTSD diagnosis.
Measures
To describe the cohort, patient and healthcare utilization characteristics were measured for FY 2008−2013. Patient characteristics included demographics, medical and psychiatric comorbidities, and military service. Healthcare utilization characteristics included percentage of patients receiving outpatient visits to primary care, general mental health, specialized PTSD clinics, substance abuse specialty clinics, as well as residential PTSD programs, substance abuse programs, and acute inpatient psychiatry settings.
To assess mortality, vital status was obtained using the VA Vital Status File, which is linked to the Corporate Data Warehouse. All deaths identified within 1 year of index PTSD diagnosis were assessed for cause of death using the VA−Department of Defense Suicide Data Repository, which links VA decedents to the Centers for Disease Control and Prevention (CDC) National Death Index. 33 Cause of death was classified using ICD-10 definitions from the CDC National Center for Health Statistics.
To allow for statistical comparison with the general population, mortality rates for the 2014 U.S. population were extracted from CDC's Wide-ranging Online Database for Epidemiologic Research (WONDER). 34 The CDC WONDER comparison population was classified by sex and three age categories (18−34 years, 35−64 years, and ≥65 years). For all-cause mortality and leading causes of death present in the study population, reference rates were obtained for age-and sex-specific strata to facilitate calculation of age-and sex-adjusted standardized mortality ratios (SMRs).
Statistical Analysis
The collected data were analyzed in two parts between September 4, 2018 and November 2, 2018. Counts of death were generated for all causes of death for Veterans in the first year of VA PTSD treatment from FY 2008 to 2013. Following National Death Index data standards, categories were suppressed where counts of death dropped below ten. This method resulted in the presentation of up to 15 leading causes of death for the study population overall and for each age group. To compare the observed mortality among PTSD Veterans with the U.S. population, age-and sexadjusted SMRs were calculated for only the top ten leading causes to ensure stable rates in the substrata. To generate a consistent comparison with CDC's WONDER, 34 all deaths were counted for Veterans who initiated VA PTSD treatment in calendar years 2008−2013. However, this time frame shift did not change the rank order of the leading causes of death.
RESULTS
Between FY 2008 and 2013, a total of 491,040 Veterans with PTSD met inclusion criteria for treatment initiation ( Table 1 ). The mean age of Veterans was 48.5 ( §16.0) years, 90.7% were male, 63.5% were white, and 60.1% were middle-aged (35−64 years). In the year after index PTSD diagnosis, 60.3% were diagnosed with comorbid depression, 39% with nicotine dependence, 22.6% with alcohol dependence, and 3.2% with opioid dependence. More than one third served in Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (34.9%) and many experienced combat (28.6%). Almost all utilized primary care (92.3%) and outpatient general mental health services (99.9%). Nearly half of Veterans with PTSD visited outpatient specialized PTSD clinics (44.6%), with a smaller percentage entering residential PTSD treatment (2.1%) or inpatient mental health (7%). During the first year of VA PTSD treatment, 5,215 Veterans died ( Table 2 ). The top three causes of death were heart disease, malignant neoplasms, and unintentional injury. The leading causes of death for young Veterans (aged 18−34 years) were unintentional injury and suicide. The leading causes of death for middle-aged Veterans (35−64 years) and older Veterans (aged ≥65 years) were heart disease and malignant neoplasms.
Given that 622 Veterans with PTSD died of unintentional injury during their first year of treatment, these injury-related deaths were described further (Table 3 ). In the entire population, the top three causes of unintentional injury deaths were poisoning, motor vehicle traffic, and falls. The leading causes of unintentional injury deaths in young Veterans and middle-aged Veterans were poisoning and motor vehicle traffic. The leading causes of unintentional injury deaths in older Veterans were falls and motor vehicle traffic.
Between calendar years 2008 and 2013, a total of 473,803 Veterans entered VA PTSD treatment and 4,782 died within 1 year. Based on the age-and sex-matched U.S. population, 4,553.7 deaths were expected because of any cause. Therefore, there was evidence of excess mortality among Veterans with PTSD compared with the U.S. population (SMR=1.05, 95% CI=1.02, 1.08, p<0.001).
Veterans with PTSD had a significant increase in mortality compared with the U.S. population for several causes of death ( 
DISCUSSION
This study outlines specific causes of excess mortality among Veterans with PTSD and stratified those causes of death by age. Compared with the U.S. population, VA users engaging in PTSD treatment had a 5% excess risk for death resulting from any cause. Accidents, suicide, and viral hepatitis were most elevated as causes of death in Veterans with PTSD compared with the U.S. population, with SMRs indicating a twofold increase in mortality for each cause of death. Diabetes mellitus and chronic liver disease were also significantly elevated as causes of death in Veterans with PTSD compared with the U.S. population. During the first year of VA treatment, young Veterans with PTSD were more likely to die of unintentional injury and suicide, whereas middleaged and older Veterans were more likely to die of cardiovascular disease and malignant neoplasms. The overall results support prior literature demonstrating an association between PTSD and excess mortality. However, the findings in this study showing a 5% excess mortality were smaller than the twofold elevated risk reported by Schlenger et al., 7 and the 58% elevated risk found by Meier and colleagues. 15 This divergence may be attributed to the selection of all-era Veterans, including a large proportion of young Veterans, across a range of PTSD treatment settings. Veterans seeking treatment for PTSD may be more inclined to seek treatment for other medical conditions, thereby mitigating potential risk factors associated with mortality. 
Other deaths include accidental injury by firearm, fire/burn, machinery, natural/environment, struck by or against. The finding that Veterans with PTSD were at elevated risk for death by suicide is consistent with prior literature. 16 Although this finding was potentially mediated by elevated rates of depression and substance abuse, 35 it does not change the fact that Veterans with PTSD were at risk for suicide. This study also demonstrated that excess mortality in patients with PTSD was largely attributed to unintentional injuries, especially among young Veterans. This relationship has not been well explored previously. Though Meier et al. 15 found that patients with PTSD had a significantly higher mortality risk because of external causes, they did not distinguish between accidents and suicide. Most unintentional injury deaths observed in this study were the result of poisoning. Given the ongoing concerns regarding potential misclassification of suicides, especially overdose deaths, 36 it may be that some of the unintentional poisonings in this cohort were in fact misclassified suicides.
Veterans with PTSD were at significantly elevated risk for death because of diabetes mellitus and chronic liver disease, which is consistent with mounting evidence supporting that PTSD may be associated with metabolic disorders. 8, 9 Patients with PTSD are prone to engage in unhealthy behaviors (22.6% of this cohort had alcohol dependence) that increase their risk for liver disease. Similar to Bullman and colleagues 14 and Drescher et al. 13 who used general population comparators, this study did not find a significantly elevated risk for death resulting from cardiovascular disease or malignancy among Veterans with PTSD compared with the U.S. population.
Although Veterans with PTSD were at elevated risk for death from viral hepatitis compared with the U.S. population, there has been relatively little study of the relationship between bloodborne pathogens and PTSD. Yet, similar to this study, Essock and colleagues 37 reported that PTSD was associated with a significant risk for HIV as well as hepatitis B and C. This finding may correlate with increasing frequency of opioid use disorder among Veterans (3.2% of this cohort had opioid dependence) with PTSD. 23, 29 This is relevant given the documented association between opioid injection and hepatitis C. 38 This study has important implications for preventive medicine. Although screening benefits must be weighed against the probability of adverse outcomes without screening, 39 patients with PTSD require greater utilization of health care 40 because of impaired functionality and comorbid medical and psychiatric illness. 41 It may therefore be less costly to intervene early. The VA currently has a PTSD screening process in place 42 and valid measures of PTSD diagnosis 30, 31, 43 ; however, less consensus regarding PTSD screening exists in the civilian population. 44 Research is needed to determine if screening instruments, such as the VA Primary Care PTSD Screen, 42 can help identify at-risk civilians. Moreover, research is needed to address the comorbidities that contribute to mortality in patients with PTSD.
The intersection of pain and PTSD may have significant clinical and programmatic implications, particularly for Veterans with PTSD. Although CDC recently issued guidelines emphasizing nonpharmacologic treatments for pain disorder, 45 Veterans with PTSD and comorbid pain may be at risk for opioid use disorder. 23 In addition to increasing the risk for hepatitis, opioids may play a role in unintentional injury and suicide, especially among Veterans with PTSD who are aged 18−34 years. Preventive efforts may need to focus on pain control as a possible target for PTSD treatment in this age group.
Treatment-seeking patients with PTSD may also benefit from more seamless transitions between care settings. 13 Among Vietnam Veterans in residential PTSD treatment, Drescher et al. 13 found that the average time from discharge to death was only 4 years. Close followup, cross-provider communication, and community integration 41 may be effective strategies to prevent PTSD-related deaths. However, more research is needed to determine if evidence-based PTSD care impacts mortality in this population.
Limitations
This study has several limitations, primarily related to sample selection and follow-up. First, the approach did not account for relevant confounders including race/ethnicity, psychiatric and medical comorbidity, and treatment. Although the cohort was started in 2008 to account for changes in VA delivery of evidence-based PTSD care, this study did not address patient-level treatment characteristics and was not designed to determine whether PTSD care affects mortality. Additional multiyear longitudinal cohorts are required to assess whether implementation of evidence-based psychotherapy for PTSD had an effect on mortality outcomes for VA users with PTSD.
Second, the results were not stratified based on military service, time from military separation to index PTSD diagnosis, area of deployment, exposure to theater of war, or trauma source. It is conceivable that each of these variables may affect PTSD severity and mitigate or worsen mortality risk. Third, the results only apply to the first year after PTSD diagnosis. Therefore, the influence of PTSD on disease may appear less severe than in subsequent years. Fourth, the PTSD cohort was included in the reference group (U.S. population) for SMR calculations. As a result, SMRs likely underestimate the differences between observed and expected deaths.
Finally, the study population was limited to U.S. Veterans. The Veteran population has demonstrated characteristics that make it unique from other PTSD populations. 46 Notably, Veterans are predominantly older and male. 46 Veterans who access the VA Health Care System are more likely to have poorer health, lower SES, and more medical conditions than the general population. 46 Therefore, these findings may not be generalizable to civilians with PTSD. It will be important that other studies replicate these results in non-Veteran populations and adjust for relevant confounders.
CONCLUSIONS
The findings suggest that Veterans with PTSD are at elevated risk for death compared with the general population, although the risk is smaller than in previous studies. Furthermore, this study fills several gaps in the literature.
The risk for death from suicide and accidents is high in Veterans with PTSD, especially among younger Veterans. Veterans with PTSD and comorbid alcohol use disorder have even greater rates of suicide. 47 Treatment of PTSD as well as co-occurring depression and substance use disorders may lessen the risk of suicide. Similarly, interventions that target PTSD and comorbid pain disorder may reduce opioid-related suicide and accidental poisoning. 23 The risk for death from diabetes, chronic liver disease, and viral hepatitis is also high in Veterans with PTSD. These conditions are associated with unhealthy lifestyle choices. Therefore, patients with PTSD should receive comprehensive education on the benefits of diet and exercise as well as the risks of chronic stress and substance use.
Finally, future studies should focus on developing and testing targeted interventions to address these risk factors to improve the overall health outcomes in patients with PTSD.
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